Kymera Therapeutics filed and disclosed patents covering new STAT6 inhibitors claimed for cancer, inflammatory and autoimmune diseases, cardiovascular disorders, neurodegeneration and viral infections. The intellectual property move strengthens Kymera’s small‑molecule portfolio and suggests a strategic push into transcription‑factor modulation across both oncology and immunology indications. Patent filings highlight chemistry and proposed utility across multiple disease areas.